PCI Pharma Services, a global CDMO focused on complex therapies, is investing more than $365 million in infrastructure supporting the clinical and commercial-scale final assembly and packaging of drug-device combination products utilizing advanced drug delivery systems, with an emphasis on injectable formats. Comprising new and expanded facilities in both Europe and North America, the effort is part of PCI’s global investment plan, is anchored and funded by recent new business, and is designed to augment and accommodate future growth.
 
PCI’s Biotech Center of Excellence in Philadelphia employs precision handling equipment for prefilled syringes, syringe assembly and labeling, vial labeling and cartoning, and autoinjector assembly. Recently, PCI invested in complex, automated advanced drug delivery technologies to enhance capabilities and capacities at this facility.
 
Combined, the new projects further bolster PCI’s ability to manage the full lifespan of such products, from sterile drug product development and manufacturing through clinical trial supply, product launch and commercialization.

New U.S. CoE

In the U.S., PCI is planning a 545,000-sq.-ft. expansion at its campus in Rockford, IL, dedicated to advanced drug delivery and drug-device combination assembly and packaging comprising 345,000 sq.-ft. for advanced drug delivery injectable packaging and 130,000 sq.-ft. of additional warehousing for products in all development phases. 
 
The space houses more than 20 customer suites, with scalable technology for the clinical and commercial-scale final assembly and packaging of vials, prefilled syringes, autoinjectors, and pen-cartridge combinations, complete with sophisticated top-open cartoning technology and extensive final assembly and functional product testing to ISO standards.
 
PCI also plans for a further 70,000-sq.-ft. expansion dedicated to advanced drug delivery and patient-centric drug-device combination assembly and packaging. The facility will support a range of low- to high-speed packaging technologies for a variety of advanced drug delivery categories, including but not limited to vials, prefilled syringes, autoinjectors and on-body injectors. The plant is intended to be brought online in two phases, with operations expected to commence in 3Q25.